Dosing Darbepoetin Alfa: Impact on Individuals Undergoing Dialysis

Frequent Use of ESA Triggers Variability in Hemoglobin Levels

Changing From rHuEPO to Darbepoetin Alfa for Renal Anemia

Consistent Effectiveness With Extended Darbepoetin Alfa Use!

Benefits of Integrating Reduced Darbepoetin Alfa Dosages for Managing Renal Anemia

Abbreviations: CKD: Chronic kidney disease; ESA: Erythropoiesis-stimulating agent; rHuEPO: Recombinant human erythropoietin.

References: 1. Agarwal AK. Darbepoetin alfa for anemia in chronic kidney disease. Expert Rev Clin Pharmacol. 2008;1(3):369–379. 2. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164–3170. 3. Cresp. Available at: https://www.cresp.in/development.html. Accessed on: 10 January 2024. 4. Alsaran K, Sabry A, Abdulghafour M, et al. The efficacy of monthly administration of darbepoetin alfa in Saudi hemodialysis patients. Dial Transplant. 2009;38(12):508–513. 5. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of Chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2(Suppl_1):i9–i17. 6. Galle JC, Addison J, Suranyi MG, et al. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: Long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant. 2016;31(12):2073–2085. 7. Palmer SC, Saglimbene V, Craig JC, et al. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014;2014(3):CD009297. 8. Bernieh B, Abouchacra S, Boobes Y, et al. Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: Target hemoglobin, variability, and outcome. Int Urol Nephrol. 2014;46(2):453–459

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-A24-0191